irinotecan + ON 01910.Na

Irinotecan is a topoisomerase I inhibitor used primarily in the treatment of metastatic colorectal cancer, either alone or in combination with other agents. It is a water-soluble derivative of camptothecin and acts by inhibiting DNA topoisomerase I, leading to DNA damage and apoptosis in rapidly dividing cells. Its active metabolite, SN-38, is significantly more potent than the parent compound. Irinotecan has also been investigated for use in small cell lung cancer and pancreatic adenocarcinoma[1][4][5]. ON 01910.Na (also known as rigosertib) is an investigational small molecule that inhibits multiple signaling pathways involved in cell cycle progression, including polo-like kinase 1 (PLK1) and PI3K pathways. The combination of irinotecan with ON 01910.Na has been studied in early-phase clinical trials for advanced solid tumors[3].

Brand names

CamptosarOnivyde

Other names

irinotecan hydrochlorideNovaplus Irinotecan Hydrochloride